Patients with germ cell tumors (GCT) progressing after first line platinum based therapy can be potentially cured with high-dose chemotherapy followed boy hematopoietic stem cell rescue (HDCT). This can be given in the form of tandem or triple courses of carboplatin and etoposide with encouraging survival rates [1] . Although there is an ongoing debate among experts whether HDCT should be the standard of care in these patients, it remains a widely employed practice [2] . Not surprisingly, given the curative potential of HDCT in GCT, secondary malignancies (SM) have been observed as a well-recognized late effect post transplant.
In this issue of Bone Marrow Transplantation, Necchi et al. [3] reported from the European Society for Blood and Marrow Transplantation (EBMT) registry, the incidence of SM following HDCT for GCT. The study included patients over 18 years of age with gonadal or extra-gonadal primary tumor origin. The primary objective was the cumulative incidence (CI) and associated risk factors for development of SM in an impressive cohort of 5218 patients treated over 3 decades and a median follow up of 3.8 years. During this time, they observed a total of 59 cases of SM, 23 of hematologic origin and 34 solid malignancies (2 additional unclassified SM cases) with corresponding time to event of 39 and 62 months, respectively. Importantly, pre-HDCT therapy including utilization of radiotherapy was not available for most patients. About half the patients received carboplatin and etoposide. Collectively, the CI of solid and hematologic malignancy at 20 years was 4.17 and 1.37%, respectively. Age over 40 years was significantly associated with the development of hematologic malignancies. Overall survival was significantly worse for patients developing hematologic malignancies, with a median of 8.6 months vs. 34.4 months.
This study represents the largest reported series of HDCT recipients for GCTs and the authors should be commended on this undertaking. SM is a well-recognized complication after HDCT and has important implications for optimal follow-up strategy and duration. Development of SM posttransplant varies significantly depending on individualized risk factors, such as age, therapeutic exposures (including pre-transplant and post-transplant), autologous vs. allogeneic transplant, development of chronic graft vs. host disease among others. It was interesting to see that hematologic but not solid malignancies were more common in transplant recipients over the age of 40, which may be due to higher incidence of clonal hematopoiesis of indeterminate potential (CHIP) with older age which has been observed to result in higher incidence of myeloid neoplasms post HDCT [4, 5] .
Global trends of the transplant activity indicate ongoing growth, coupled with improved transplant survivorship due to enhanced supportive care and other factors led to significant increase in patients with potential late effects such as SM [6] . Recognizing this emerging challenge, leading experts in the transplant community published recommendations for screening and preventive practices in such survivors [7] . Furthermore, a collaborative effort of the Center of International Blood and Marrow Transplant Research (CIBMTR) and the EBMT offered consensus based recommendations applicable for preventive screening for solid cancers among transplant recipients [8] . More recently, the subsequent neoplasm working group, one of six groups commissioned by the National Institute of Health (NIH) to address the research needs and best practices for late effects post transplantation, described the current state of evidence regarding SN development and suggested approaches and recommendations on how to overcome challenges and set research priorities [9] . The common theme is the need for heightened surveillance to prevent or manage a number of common issues arising post transplant. It is important to emphasize that these guidelines were founded on an evidence base largely driven by extrapolation from literature for cancer screening in the general population as well as expert recommendations.
The incidence of SM in other hematologic malignancies post HDCT was previously described. Tarella et al. [10] , reported on 1024 patients with lymphoma at 11 Italian centers that after a median follow up of 7 years, the CI of hematologic neoplasms at 5 and 10 years to be 3.09 and 4.52% whereas that of solid tumors at 2.54 and 6.79%, respectively. Conversely, Krishnan et al., reported on 841 patients from a single center post autologous transplant recipients for multiple myeloma a CI of SM at 5.3 and 11.2% at 5 and 10 years, respectively [11] . The total incidence was even higher after accounting for non-melanoma skin cancers. It is plausible that exposure to immunomodulatory (IMIDs) drugs thalidomide and lenalidomide may have accounted for this elevated risk; however, over half of the patients received transplant prior to the IMID era. Such high discrepancy in the incidence of SM between diseases likely reflects the risk factors and exposures but also importantly the degree of active surveillance post-transplant in patients "cured from their disease". For example, it is speculative but conceivable that patients with multiple myeloma were followed more rigorously for maintenance or salvage therapy, whereas many lymphoma or GCT recipients are cured and may not be followed in the transplant center long term-thus potentially "missing" some SM cases.
As GCT are typically treated with two to three courses of HDCT, with over 2 g/m 2 of etoposide with each course, it is surprising to see the CI reported by Necchi et al., to be lower than expected compared to transplant recipients of other malignancies. Furthermore, the limited number of cases did not permit computing a multivariable analysis thus risk factor assessment was not complete. Consequently, it is important to highlight a number of observations and venture that it may have led to underestimation of the actual incidence. Firstly, the median follow up of this cohort was only 3.8 years despite the majority of transplants being done prior to 2010; indicating high proportion of lost to follow up. Furthermore, the incidence of SM does not seem to plateau over time, especially for detection of solid SM, underscoring the need for long term follow up to capture most cases. Second, the pre-HDCT exposures were not defined and about 40% of patients had missing information regarding conditioning regimens. Such information is critical as the development of SM is greatly impacted by prior therapies and this was an additional impediment towards risk factor assessment. Despite these factors, it is clear that the risk of SM development in GCT recipients of HDCT is ongoing and this report will help the clinician to better counsel and plan follow up for patients.
Historically, transplant experts were the primary providers for these patients but more recently, other specialties including primary care, are increasingly being involved. Such preventive care is ideally delivered through dedicated multidisciplinary long term follow up clinics providing risk adapted life-long screening and surveillance [12] . Formidable challenges remain with regards to the best model of such clinics and issues such as system capacity, responsibility designation, and administrative services among others should be resolved to fit each center's unique setup. Taken together, the transplant community has made considerable steps towards understanding the onset and course of late effects enabling us to identify ongoing needs and provide timely interventions. Currently, we need to continue implementing such knowledge in clinical care for prevention or early management of such premature health threats, among which new cancers remain the top offender.
